Corbus Pharmaceuticals' treatment for metastatic cervical cancer, CRB-701, has received fast-track designation from the FDA. The drug targets Nectin-4 overexpression in cancers, with first trial data expected in 2025.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
